Literature DB >> 22689673

Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma.

Jens Hillengass1, Sofia Ayyaz, Kerstin Kilk, Marc-André Weber, Thomas Hielscher, Rajiv Shah, Dirk Hose, Stefan Delorme, Hartmut Goldschmidt, Kai Neben.   

Abstract

In multiple myeloma, focal lesions, as well as diffuse and variegated infiltration patterns, can be detected by magnetic resonance imaging. In the current study, we compared treatment response in 100 myeloma patients with changes in infiltration patterns in whole body magnetic resonance imaging before and after autologous stem cell transplantation. We found an agreement between serological response and changes in imaging (P<0.001). In detail, a significant agreement of treatment response was observed for diffuse (P=0.004) as well as for focal (P=0.01) infiltration patterns. The number of focal lesions at second magnetic resonance imaging was of prognostic significance for overall survival (P=0.001). We conclude that treatment response in myeloma goes along with a decrease in imaging findings. We suggest that residual disease after high-dose chemotherapy detected by magnetic resonance imaging increases the risk of relapse. Therefore, myeloma patients with such findings after treatment might benefit from further cytoreduction.

Entities:  

Mesh:

Year:  2012        PMID: 22689673      PMCID: PMC3487452          DOI: 10.3324/haematol.2012.065359

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  22 in total

1.  Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.

Authors:  Kai Neben; Henk M Lokhorst; Anna Jauch; Uta Bertsch; Thomas Hielscher; Bronno van der Holt; Hans Salwender; Igor W Blau; Katja Weisel; Michael Pfreundschuh; Christof Scheid; Ulrich Dührsen; Walter Lindemann; Ingo G H Schmidt-Wolf; Norma Peter; Christian Teschendorf; Hans Martin; Mathias Haenel; Hans G Derigs; Marc S Raab; Anthony D Ho; Helgi van de Velde; Dirk Hose; Pieter Sonneveld; Hartmut Goldschmidt
Journal:  Blood       Date:  2011-12-08       Impact factor: 22.113

2.  A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.

Authors:  Elena Zamagni; Cristina Nanni; Francesca Patriarca; Emanuela Englaro; Paolo Castellucci; Onelio Geatti; Patrizia Tosi; Paola Tacchetti; Delia Cangini; Giulia Perrone; Michela Ceccolini; Annamaria Brioli; Silvia Buttignol; Renato Fanin; Eugenio Salizzoni; Michele Baccarani; Stefano Fanti; Michele Cavo
Journal:  Haematologica       Date:  2007-01       Impact factor: 9.941

3.  Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey.

Authors:  Nadir Ghanem; Christian Lohrmann; Monika Engelhardt; Gregor Pache; Markus Uhl; Ulrich Saueressig; Elmar Kotter; Mathias Langer
Journal:  Eur Radiol       Date:  2006-02-04       Impact factor: 5.315

4.  Magnetic resonance imaging patterns in patients with multiple myeloma.

Authors:  S Kusumoto; I Jinnai; K Itoh; N Kawai; T Sakata; A Matsuda; K Tominaga; I Murohashi; M Bessho; K Harashima; A Heshiki
Journal:  Br J Haematol       Date:  1997-12       Impact factor: 6.998

5.  Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma.

Authors:  L A Moulopoulos; D Gika; A Anagnostopoulos; K Delasalle; D Weber; R Alexanian; M A Dimopoulos
Journal:  Ann Oncol       Date:  2005-08-08       Impact factor: 32.976

6.  Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma.

Authors:  X Mariette; A M Zagdanski; A Guermazi; C Bergot; A Arnould; J Frija; J C Brouet; J P Fermand
Journal:  Br J Haematol       Date:  1999-03       Impact factor: 6.998

7.  International uniform response criteria for multiple myeloma.

Authors:  B G M Durie; J-L Harousseau; J S Miguel; J Bladé; B Barlogie; K Anderson; M Gertz; M Dimopoulos; J Westin; P Sonneveld; H Ludwig; G Gahrton; M Beksac; J Crowley; A Belch; M Boccadaro; M Cavo; I Turesson; D Joshua; D Vesole; R Kyle; R Alexanian; G Tricot; M Attal; G Merlini; R Powles; P Richardson; K Shimizu; P Tosi; G Morgan; S V Rajkumar
Journal:  Leukemia       Date:  2006-07-20       Impact factor: 11.528

8.  Dynamic contrast-enhanced MRI for assessing the disease activity of multiple myeloma: a comparative study with histology and clinical markers.

Authors:  Sílvia Nosàs-Garcia; Thomas Moehler; Klaus Wasser; Fabian Kiessling; Reiner Bartl; Ivan Zuna; Jens Hillengass; Hartmut Goldschmidt; Hans-Ulrich Kauczor; Stefan Delorme
Journal:  J Magn Reson Imaging       Date:  2005-07       Impact factor: 4.813

9.  Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.

Authors:  Ronald Walker; Bart Barlogie; Jeffrey Haessler; Guido Tricot; Elias Anaissie; John D Shaughnessy; Joshua Epstein; Rudy van Hemert; Eren Erdem; Antje Hoering; John Crowley; Ernest Ferris; Klaus Hollmig; Frits van Rhee; Maurizio Zangari; Mauricio Pineda-Roman; Abid Mohiuddin; Shmuel Yaccoby; Jeffrey Sawyer; Edgardo J Angtuaco
Journal:  J Clin Oncol       Date:  2007-02-12       Impact factor: 44.544

10.  Stage III multiple myeloma: clinical and prognostic value of spinal bone marrow MR imaging.

Authors:  F E Lecouvet; B C Vande Berg; L Michaux; J Malghem; B E Maldague; J Jamart; A Ferrant; J L Michaux
Journal:  Radiology       Date:  1998-12       Impact factor: 11.105

View more
  33 in total

1.  Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance.

Authors:  J Hillengass; M-A Weber; K Kilk; K Listl; B Wagner-Gund; M Hillengass; T Hielscher; A Farid; K Neben; S Delorme; O Landgren; H Goldschmidt
Journal:  Leukemia       Date:  2013-08-20       Impact factor: 11.528

Review 2.  New criteria for response assessment: role of minimal residual disease in multiple myeloma.

Authors:  Bruno Paiva; Jacques J M van Dongen; Alberto Orfao
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

Review 3.  Prognostic significance of focal lesions and diffuse infiltration on MRI for multiple myeloma: a meta-analysis.

Authors:  So-Yeon Lee; Hyun-Jung Kim; Yu Ri Shin; Hee-Jin Park; Yun-Gyoo Lee; Suk Joong Oh
Journal:  Eur Radiol       Date:  2016-09-05       Impact factor: 5.315

Review 4.  Whole-body MRI, dynamic contrast-enhanced MRI, and diffusion-weighted imaging for the staging of multiple myeloma.

Authors:  Julie C Dutoit; Koenraad L Verstraete
Journal:  Skeletal Radiol       Date:  2017-03-13       Impact factor: 2.199

5.  [Imaging in smoldering (asymptomatic) multiple myeloma. Past, present and future].

Authors:  M Bhutani; O Landgren
Journal:  Radiologe       Date:  2014-06       Impact factor: 0.635

Review 6.  Imaging in myeloma with focus on advanced imaging techniques.

Authors:  Tara Barwick; Laure Bretsztajn; Kathryn Wallitt; Dimitri Amiras; Andrea Rockall; Christina Messiou
Journal:  Br J Radiol       Date:  2019-01-03       Impact factor: 3.039

Review 7.  Myeloma and Bone Disease.

Authors:  Cristina Panaroni; Andrew J Yee; Noopur S Raje
Journal:  Curr Osteoporos Rep       Date:  2017-10       Impact factor: 5.096

8.  [Focal lesions in whole-body MRI in multiple myeloma : Quantification of tumor mass and correlation with disease-related parameters and prognosis].

Authors:  S C Brandelik; J Krzykalla; T Hielscher; J Hillengass; J K Kloth; H U Kauczor; M A Weber
Journal:  Radiologe       Date:  2018-01       Impact factor: 0.635

9.  18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study.

Authors:  Thibaut Cassou-Mounat; Sona Balogova; Valérie Nataf; Marie Calzada; Virginie Huchet; Khaldoun Kerrou; Jean-Yves Devaux; Mohamad Mohty; Jean-Noël Talbot; Laurent Garderet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-28       Impact factor: 9.236

Review 10.  ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.

Authors:  Franco Dammacco; Giuseppe Rubini; Cristina Ferrari; Angelo Vacca; Vito Racanelli
Journal:  Clin Exp Med       Date:  2014-09-14       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.